These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 18684735)

  • 41. Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction.
    La Marca A; D'Ippolito G
    Reprod Biomed Online; 2014 Feb; 28(2):183-90. PubMed ID: 24368127
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles.
    Oehninger S; Nelson SM; Verweij P; Stegmann BJ
    Reprod Biol Endocrinol; 2015 Oct; 13():117. PubMed ID: 26520396
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Short follicular phase of stimulation following corifollitropin alfa or daily recombinant FSH treatment does not compromise clinical outcome: a retrospective analysis of the Engage trial.
    Mardešič T; Mannaerts B; Abuzeid M; Levy M; Witjes H; Fauser BC;
    Reprod Biomed Online; 2014 Apr; 28(4):462-8. PubMed ID: 24581989
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimizing the gonadotrophin dose regimen.
    Out HJ; Thomas LE
    Int Surg; 2006; 91(5 Suppl):S15-24. PubMed ID: 17436601
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the follicular output rate after controlled ovarian stimulation with daily recombinant follicle-stimulating hormone versus corifollitropin alfa.
    Griesinger G; Teal V; McCrary Sisk C; Ruman J
    Eur J Obstet Gynecol Reprod Biol; 2019 Jan; 232():101-105. PubMed ID: 30529793
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Gonadotrophin dose and ovarian response: relations to the clinical outcome of in vitro fertilization and embryo transfer].
    Xiong XS; Chen SL; Sun L; Yin MN; Zhao EY; Song J
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):712-4. PubMed ID: 18504186
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ovarian stimulation with corifollitropin alfa followed by hp-hMG compared to hp-hMG in patients at risk of poor ovarian response undergoing ICSI: A randomized controlled trial.
    Taronger R; Martínez-Cuenca S; Ferreros I; Rubio JM; Fernández-Colom PJ; Martínez-Triguero ML; Pellicer A
    Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():192-197. PubMed ID: 30428403
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis.
    Fensore S; Di Marzio M; Tiboni GM
    J Ovarian Res; 2015 Jun; 8():33. PubMed ID: 26036214
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of two different fixed doses of follitropin-beta in controlled ovarian hyperstimulation: A prospective randomized, double blind clinical trial.
    Pruksananonda K; Suwajanakorn S; Sereepapong W; Virutamasen P
    J Med Assoc Thai; 2004 Oct; 87(10):1151-5. PubMed ID: 15560689
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Corifollitropin alfa: a novel long-acting recombinant follicle-stimulating hormone agonist for controlled ovarian stimulation.
    Loutradis D; Vlismas A; Drakakis P
    Womens Health (Lond); 2010 Sep; 6(5):655-64. PubMed ID: 20887164
    [TBL] [Abstract][Full Text] [Related]  

  • 51. No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part I, corifollitropin alfa.
    Doody KJ; Devroey P; Leader A; Witjes H; Mannaerts BM
    Reprod Biomed Online; 2011 Oct; 23(4):449-56. PubMed ID: 21856230
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Corifollitropin alfa or rFSH treatment flexibility options for controlled ovarian stimulation: a post hoc analysis of the Engage trial.
    Leader A; Devroey P; Witjes H; Gordon K
    Reprod Biol Endocrinol; 2013 Jun; 11():52. PubMed ID: 23758821
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Patient Friendly Corifollitropin Alfa Protocol without Routine Pituitary Suppression in Normal Responders.
    Wang HL; Lai HH; Chuang TH; Shih YW; Huang SC; Lee MJ; Chen SU
    PLoS One; 2016; 11(4):e0154123. PubMed ID: 27100388
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of the efficacy and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha (Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology.
    Moon SY; Choi YS; Ku SY; Kim SH; Choi YM; Kang IS; Kim CH
    J Obstet Gynaecol Res; 2007 Jun; 33(3):305-15. PubMed ID: 17578360
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of frozen-thawed embryo transfer in women aged 35 to 42 years from the PURSUE randomized clinical trial.
    Boostanfar R; Gates D; Guan Y; Gordon K; McCrary Sisk C; Stegmann BJ
    Fertil Steril; 2016 Aug; 106(2):300-305.e5. PubMed ID: 27090863
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment--recombinant HCG versus urinary HCG. The European Recombinant Human Chorionic Gonadotrophin Study Group.
    Hum Reprod; 2000 Jul; 15(7):1446-51. PubMed ID: 10875887
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pituitary suppression protocol among Bologna poor responders undergoing ovarian stimulation using corifollitropin alfa: does it play any role?
    Errázuriz J; Drakopoulos P; Pening D; Racca A; Romito A; De Munck N; Tournaye H; De Vos M; Blockeel C
    Reprod Biomed Online; 2019 Jun; 38(6):1010-1017. PubMed ID: 30879911
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity.
    Norman RJ; Zegers-Hochschild F; Salle BS; Elbers J; Heijnen E; Marintcheva-Petrova M; Mannaerts B;
    Hum Reprod; 2011 Aug; 26(8):2200-8. PubMed ID: 21622693
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intercycle variability of the ovarian response in patients undergoing repeated stimulation with corifollitropin alfa in a gonadotropin-releasing hormone antagonist protocol.
    Rombauts L; Lambalk CB; Schultze-Mosgau A; van Kuijk J; Verweij P; Gates D; Gordon K; Griesinger G
    Fertil Steril; 2015 Oct; 104(4):884-890.e2. PubMed ID: 26187300
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparison of 3-day and daily follicle-stimulating hormone injections on stimulation days 1-6 in women undergoing controlled ovarian hyperstimulation.
    Scholtes MC; Schnittert B; van Hoogstraten D; Verhoeven HC; Zrener A; Warne DW
    Fertil Steril; 2004 Apr; 81(4):996-1001. PubMed ID: 15066454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.